ALZCHEM GROUP AG (ACT.DE) Stock Fundamental Analysis
Europe • Frankfurt Stock Exchange • FRA:ACT • DE000A2YNT30
154.6 EUR
-2.8 (-1.78%)
Last: Jan 30, 2026, 05:36 PM
Taking everything into account, ACT scores 7 out of 10 in our fundamental rating. ACT was compared to 71 industry peers in the Chemicals industry. Both the health and profitability get an excellent rating, making ACT a very profitable company, without any liquidiy or solvency issues. While showing a medium growth rate, ACT is valued expensive at the moment. With these ratings, ACT could be worth investigating further for quality investing!.
1. Profitability
1.1 Basic Checks
- ACT had positive earnings in the past year.
- ACT had a positive operating cash flow in the past year.
- ACT had positive earnings in each of the past 5 years.
- Of the past 5 years ACT 4 years had a positive operating cash flow.
1.2 Ratios
- ACT has a better Return On Assets (10.49%) than 94.37% of its industry peers.
- ACT has a Return On Equity of 26.47%. This is amongst the best in the industry. ACT outperforms 94.37% of its industry peers.
- With an excellent Return On Invested Capital value of 13.45%, ACT belongs to the best of the industry, outperforming 91.55% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for ACT is above the industry average of 7.19%.
- The last Return On Invested Capital (13.45%) for ACT is above the 3 year average (12.06%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.49% | ||
| ROE | 26.47% | ||
| ROIC | 13.45% |
ROA(3y)8.81%
ROA(5y)7.86%
ROE(3y)22.87%
ROE(5y)25.91%
ROIC(3y)12.06%
ROIC(5y)10.63%
1.3 Margins
- ACT has a better Profit Margin (10.97%) than 81.69% of its industry peers.
- In the last couple of years the Profit Margin of ACT has grown nicely.
- ACT's Operating Margin of 15.93% is amongst the best of the industry. ACT outperforms 83.10% of its industry peers.
- ACT's Operating Margin has improved in the last couple of years.
- Looking at the Gross Margin, with a value of 66.55%, ACT belongs to the top of the industry, outperforming 97.18% of the companies in the same industry.
- In the last couple of years the Gross Margin of ACT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.93% | ||
| PM (TTM) | 10.97% | ||
| GM | 66.55% |
OM growth 3Y17.53%
OM growth 5Y12.4%
PM growth 3Y14.29%
PM growth 5Y15.31%
GM growth 3Y2.01%
GM growth 5Y1.44%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), ACT is creating value.
- Compared to 1 year ago, ACT has less shares outstanding
- Compared to 5 years ago, ACT has less shares outstanding
- The debt/assets ratio for ACT has been reduced compared to a year ago.
2.2 Solvency
- An Altman-Z score of 5.08 indicates that ACT is not in any danger for bankruptcy at the moment.
- ACT's Altman-Z score of 5.08 is amongst the best of the industry. ACT outperforms 88.73% of its industry peers.
- ACT has a debt to FCF ratio of 1.32. This is a very positive value and a sign of high solvency as it would only need 1.32 years to pay back of all of its debts.
- The Debt to FCF ratio of ACT (1.32) is better than 94.37% of its industry peers.
- ACT has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
- The Debt to Equity ratio of ACT (0.16) is better than 73.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 1.32 | ||
| Altman-Z | 5.08 |
ROIC/WACC1.84
WACC7.3%
2.3 Liquidity
- ACT has a Current Ratio of 2.87. This indicates that ACT is financially healthy and has no problem in meeting its short term obligations.
- ACT has a Current ratio of 2.87. This is amongst the best in the industry. ACT outperforms 83.10% of its industry peers.
- ACT has a Quick Ratio of 1.77. This is a normal value and indicates that ACT is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 1.77, ACT belongs to the top of the industry, outperforming 81.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.87 | ||
| Quick Ratio | 1.77 |
3. Growth
3.1 Past
- ACT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.12%, which is quite impressive.
- The Earnings Per Share has been growing by 24.60% on average over the past years. This is a very strong growth
- Looking at the last year, ACT shows a small growth in Revenue. The Revenue has grown by 1.05% in the last year.
- The Revenue has been growing by 8.06% on average over the past years. This is quite good.
EPS 1Y (TTM)24.12%
EPS 3Y25.02%
EPS 5Y24.6%
EPS Q2Q%31.66%
Revenue 1Y (TTM)1.05%
Revenue growth 3Y9.49%
Revenue growth 5Y8.06%
Sales Q2Q%6.46%
3.2 Future
- The Earnings Per Share is expected to grow by 20.26% on average over the next years. This is a very strong growth
- The Revenue is expected to grow by 6.02% on average over the next years.
EPS Next Y21.07%
EPS Next 2Y12.7%
EPS Next 3Y18.06%
EPS Next 5Y20.26%
Revenue Next Year2.51%
Revenue Next 2Y5.13%
Revenue Next 3Y8.61%
Revenue Next 5Y6.02%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 25.34 indicates a quite expensive valuation of ACT.
- The rest of the industry has a similar Price/Earnings ratio as ACT.
- The average S&P500 Price/Earnings ratio is at 28.39. ACT is around the same levels.
- With a Price/Forward Earnings ratio of 23.89, ACT is valued on the expensive side.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of ACT is on the same level as its industry peers.
- When comparing the Price/Forward Earnings ratio of ACT to the average of the S&P500 Index (25.72), we can say ACT is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.34 | ||
| Fwd PE | 23.89 |
4.2 Price Multiples
- ACT's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. ACT is more expensive than 60.56% of the companies in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of ACT is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 44.98 | ||
| EV/EBITDA | 13.51 |
4.3 Compensation for Growth
- The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- ACT has an outstanding profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as ACT's earnings are expected to grow with 18.06% in the coming years.
PEG (NY)1.2
PEG (5Y)1.03
EPS Next 2Y12.7%
EPS Next 3Y18.06%
5. Dividend
5.1 Amount
- With a Yearly Dividend Yield of 1.16%, ACT has a reasonable but not impressive dividend return.
- ACT's Dividend Yield is slightly below the industry average, which is at 2.45.
- Compared to the average S&P500 Dividend Yield of 1.82, ACT is paying slightly less dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.16% |
5.2 History
- The dividend of ACT has a limited annual growth rate of 6.00%.
Dividend Growth(5Y)6%
Div Incr Years5
Div Non Decr Years5
5.3 Sustainability
- ACT pays out 49.16% of its income as dividend. This is a bit on the high side, but may be sustainable.
- The dividend of ACT is growing, but earnings are growing more, so the dividend growth is sustainable.
DP49.16%
EPS Next 2Y12.7%
EPS Next 3Y18.06%
ALZCHEM GROUP AG / ACT.DE FAQ
Can you provide the ChartMill fundamental rating for ALZCHEM GROUP AG?
ChartMill assigns a fundamental rating of 7 / 10 to ACT.DE.
What is the valuation status for ACT stock?
ChartMill assigns a valuation rating of 3 / 10 to ALZCHEM GROUP AG (ACT.DE). This can be considered as Overvalued.
Can you provide the profitability details for ALZCHEM GROUP AG?
ALZCHEM GROUP AG (ACT.DE) has a profitability rating of 9 / 10.
Can you provide the financial health for ACT stock?
The financial health rating of ALZCHEM GROUP AG (ACT.DE) is 9 / 10.
What is the earnings growth outlook for ALZCHEM GROUP AG?
The Earnings per Share (EPS) of ALZCHEM GROUP AG (ACT.DE) is expected to grow by 21.07% in the next year.